GLP-1s aid knee osteoarthritis but raise long-term concerns

Recent studies show that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) can reduce knee osteoarthritis (KOA) pain, primarily through weight loss. However, conflicting data raises concerns about potential long-term adverse effects of these medications. Some research indicates that GLP-1 RAs may worsen osteoarthritis, while other studies suggest they help reduce the need for knee surgeries. The differences in findings stem from variations in study populations and methodologies, complicating comparisons. Experts emphasize the need for more long-term data to understand the full impact of GLP-1 RAs on osteoarthritis. Current evidence shows short-term benefits, but the long-term effects remain uncertain.